Paeds Vivas · adolescent-and-young-adult-medicine
Adolescent substance-use screening, brief intervention and harm reduction — branching viva
Branching viva on universal substance-use screening (S2BI/CRAFFT), motivational-interviewing brief intervention, the fentanyl-era opioid harm-reduction bundle, vaping cessation, and a confidentiality decision.
On this page
Study tools
Target exams
RACP General PaediatricsRACP DCEMRCPCH ClinicalRCPSC Pediatrics
Prompt
You are the paediatric registrar in a youth-friendly clinic. The examiner will move from SBIRT philosophy to universal screening, a positive cannabis/vaping lead, a fentanyl-era opioid disclosure, and a confidentiality dilemma.
Stem
The examiner will test whether you can run SBIRT under pressure and defend harm reduction as a clinical philosophy rather than an excuse. [3] [1]
References7ShowHide
- [1]Levy SJ, Williams JF Substance Use Screening, Brief Intervention, and Referral to Treatment. Pediatrics, 2016.PMID 27325634
- [2]Knight JR, Sherritt L, Shrier LA, Harris SK, Chang G Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Archives of pediatrics & adolescent medicine, 2002.PMID 12038895
- [3]Kimmel SD, Gaeta JM, Hadland SE, Hallett E, Marshall BDL Principles of Harm Reduction for Young People Who Use Drugs. Pediatrics, 2021.PMID 33386326
- [4]Chadi N, Hadland SE Youth Access to Naloxone: The Next Frontier? The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2019.PMID 31648752
- [5]Cushing CC, Jensen CD, Miller MB, Leffingwell TR Meta-analysis of motivational interviewing for adolescent health behavior: efficacy beyond substance use. Journal of consulting and clinical psychology, 2014.PMID 24841861
- [6]Winer JM, Yule AM, Hadland SE, Bagley SM Addressing adolescent substance use with a public health prevention framework: the case for harm reduction. Annals of medicine, 2022.PMID 35900132
- [7]Evins AE, Cather C, Reeder HT, et al. Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial. JAMA, 2025.PMID 40266580